Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

<strong>Background</strong> Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or...

Full description

Bibliographic Details
Main Authors:	Thwaites, GE, Scarborough, M, Szubert, AJ, Nsutebu, E, Tilley, R, Greig, J, Wyllie, SA, Wilson, P, Auckland, C, Cairns, J, Ward, D, Lal, P, Guleri, A, Jenkins, N, Sutton, J, Wilselka, M, Armando, G-R, Graham, C, Chadwick, PR, Barlow, G, Gordon, NC, Young, B, Meisner, S, McWhinney, P, Price, DA, Harvey, D, Nayar, D, Jeyaratnam, D, Planche, T, Minton, J, Hudson, F, Hopkins, S, Williams, J, Torok, ME, Llewelyn, MJ, Edgeworth, JD, Walker, AS
Format:	Journal article
Published:	Elsevier 2017

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

Similar Items